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Economic evaluations of psychosocial interventions are uncommon in cancer care and 
this is an important area of further research(1).  Lemieux J et al report (2006 100:183-
190) an economic analysis of psychosocial group therapy in women with advanced-
stage breast cancer.  We would like to comment on a few issues raised in this paper. 
 
The authors summarised the evidence suggesting psychological distress is associated 
with increased utilisation of health care resources.  The number and associated costs 
of primary care visits may be reduced if participants receiving a psychosocial 
intervention have their supportive care needs (i.e., worries, concerns, coping 
solutions) met which they usually obtain from their primary care physician.  Such an 
intervention may also reduce the need or demand for pharmacotherapies hence 
medication costs may also be lower amongst the intervention group. Also, doctors 
may not prescribe medications so readily if they know a counsellor is involved(2).  
Conversely, as the authors have acknowledged, a psychosocial intervention may 
actually encourage a participant to attend their family physician or oncologist more 
frequently for pharmacological support and optimal oncological care.  Therefore, the 
inclusion of primary care physician visits within assessments of health care costs is 
paramount for understanding patterns of health care utilisation. Economic evaluations 
are often constrained by the availability of data sources, however, any such efforts in 
the future should aim to collect primary care physician visits to improve the internal 
validity of a cost-analysis.  Therefore, it is unfortunate that Lemieux J et al’s study 
investigated adjuvant therapies, hospitalisations, and diagnostic procedures only. It 
seems unlikely that these health care resources will differ depending on whether or 
not women received a supportive care intervention as they most commonly form part 
of standardised treatment protocols.   
 
Irrespective of the sample size the typical distribution of cost data is right-skewed(3), 
and from Lemieux et al’s data in Tables 3 this is also the case for their study. Newer 
techniques for such data are now popular in economic evaluations, such as 
bootstrapping methods and two-stage regression techniques (3) which circumvent the 
problems of interpreting transformed data and non-parametric tests.  This analysis 
could have further increased our understanding of costs for women with advanced-
stage breast cancer if adjustment for important confounders were considered, such as 
ability to pay, insurance status, access and availability to health services. 
 
Lastly, it is interesting to read that Lemieux et al’s expected the psychosocial group 
therapy intervention to be cost-saving.  Interventions aimed to produce increased 
health outcomes usually do so at increased costs. From the patients’ and health 
provider’s point of view, it is important to ask whether the added health benefits 
attributable to the intervention outweigh their potentially higher costs.  Therefore, 
rather than perform a cost-minimization analysis, quality-adjusted life-years could 
have been considered an appropriate health outcome for patients with advanced-stage 
breast cancer receiving a psychosocial intervention.  Again, future studies should 
consider using a utility-based quality of life measure to allow appropriate calculation 
of quality-adjusted life-years when quality of life comes to the forefront of health care 
and when survival gains are improbable(4). This outcome which is used widely in 
economic evaluations would have further enabled some comparisons with previous 
studies.  
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